ClinicalTrials.gg
Not yet recruitingNCT07950462Updated Nov 20, 2026

A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity

A Phase 1 interventional study of QLS7402 Injection and Placebo control in Overweight or Obesity, sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity

Read the detailed description

This is a first-in-human (FIH), randomized, double-blind, placebo-controlled Phase 1 clinical study of QLS7402 injection, which consists of a single ascending dose (SAD) study in adult participants with overweight or obesity. The study is designed to evaluate the safety, tolerability, PK, and PD of QLS7402 following single subcutaneous administration. In accordance with the dose escalation principle, dose escalation will proceed sequentially from the starting dose to higher dose levels. An individual trial participant will receive only one dose level as a single dose. This study is designed with 5 prespecified escalating dose groups.

02

Conditions studied

  • Overweight or Obesity

Browse trials for

03

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.

This study's planned enrollment of 40 is below the median of 68 across 9,040 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD is the lead sponsor of 9 studies on the registry; 9 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1)Willing to participate in this study and provide written prior to any study-specific procedures; able to understand the study procedures, methods, requirements, and restrictions; and willing to comply with the protocol and complete the study.
  • 2) Male and female adults aged between 18 and 55 years, inclusive, at the time of informed consent.
  • 3) 27.0 kg/m²≤\<35.0 kg/m² at screening.
  • 4) Body weight has remained stable for at least 3 months prior to screening(defined as a weight change within ±5%, participant self-reported information is acceptable).

Exclusion criteria

Exclusion Criteria:

  • 1) Evidence or history or presence of major diseases, including but not limited to disorders involving the cardiovascular, endocrine (except for primary obesity and mild to moderate hepatic steatosis with normal hepatic function), psychiatric, neurological, gastrointestinal, respiratory, hematological, immunological, urogenital, renal, hepatic, pulmonary, or dermatological systems, or any other condition that, in the judgment of the Investigator, makes the participant unsuitable for this study.
  • 2) History of endocrine disorders that may significantly affect body weight (e.g., Cushing's syndrome, hypothalamic obesity, hypothyroidism, or hyperthyroidism), or history of medication-induced obesity, monogenic obesity, or hereditary obesity syndromes.
  • 3) History of .
  • 4) Skin conditions and/or tattoos that may interfere with the evaluation of injection site reactions, or abdominal scarring (e.g., due to surgery or burns) that may affect subcutaneous administration; intolerance to subcutaneous injection which, in the investigator's opinion, may preclude study drug administration or local tolerability assessment.
  • 5) Difficult venous access (e.g., history of needle phobia or blood phobia), or poor venous conditions that, in the judgment of the Investigator, render the participant unsuitable for enrollment.
  • 6) History of or planned any form of bariatric surgery or device-based treatment for obesity during the study period; severe trauma or major surgery within 6 months prior to screening; or planned surgery during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    QLS7402

    QLS7402 Injection

    Drug: QLS7402 Injection

  • Placebo comparator
    Placebo

    Placebo Control

    Drug: Placebo control

Interventions

  • DrugQLS7402 Injection

    QLS7402 Injection

  • DrugPlacebo control

    Placebo Control

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: 169 days

  2. Number of participants with treatment-related adverse events (TRAEs)

    Time frame: 169 days

  3. Number of participants with serious adverse events (SAEs)

    Time frame: 169 days

  4. Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory tests

    Time frame: 169 days

Secondary outcomes

  1. The change from baseline in Maximum Plasma Concentration (Cmax)

    Time frame: 3 days

  2. The change from baseline in Activin E levels

    Time frame: 169 days

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 20, 2026
StartEst.
Jan 13, 2027
Primary completionEst.
Oct 29, 2027
CompletionEst.
Apr 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07950462
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Jan 13, 2027 (estimated)
Primary completion
Oct 29, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Qing wen, Master of Medicine
Contact
wenq0619@126.com
+86-13370551767

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion